Challenges in Implementing Hospice Clinical Trials: Preserving Scientific Integrity While Facing Change

被引:16
|
作者
Oliver, Debra Parker [1 ]
Washington, Karla T. [1 ]
Demiris, George [2 ]
White, Patrick [3 ]
机构
[1] Univ Missouri, Dept Family & Community Med, One Univ Dr,MA 306G, Columbia, MO 65203 USA
[2] Univ Penn, Sch Nursing, Dept Biobehav Hlth Sci, Philadelphia, PA 19104 USA
[3] Washington Univ, Sch Med, Dept Internal Med, Div Palliat Med,Palliat Med & Support Care, St Louis, MO 63110 USA
关键词
Hospice clinical trial; cluster crossover designs in hospice; pragmatic randomized clinical trials; CLUSTER RANDOMIZATION; CARE; DESIGN;
D O I
10.1016/j.jpainsymman.2019.09.028
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Background/Aims. Numerous changes can occur between the original design plans for clinical trials, the submission of funding proposals, and the implementation of the clinical trial. In the hospice setting, environmental changes can present significant obstacles, which require changes to the original plan designs, recruitment, and staffing. The purpose of the study was to share lessons and problem-solving strategies that can assist in future hospice trials. Methods. This study uses one hospice clinical trial as an exemplar to demonstrate challenges for clinical trial research in this setting. Using preliminary data collected during the first months of a trial, the research team details the many ways their current protocol reflects changes from the originally proposed plans. Experiences are used as an exemplar to address the following questions: 1) How do research environments change between the initial submission of a funding proposal and the eventual award? 2) How can investigators maintain the integrity of the research and accommodate unexpected changes in the research environment? Results. The changing environment within the hospice setting required design, sampling, and recruitment changes within the first year. The decision-making process resulted in a stronger design with greater generalization. As a result of necessary protocol changes, the study results are positioned to be translational following the study conclusion. Conclusion. Researchers would do well to review their protocol and statistics early in a clinical trial. They should be prepared for adjustments to accommodate market and environmental changes outside their control. Ongoing data monitoring, specifically related to recruitment, is advised. (C) 2019 American Academy of Hospice and Palliative Medicine. Published by Elsevier Inc. All rights reserved.
引用
收藏
页码:365 / 371
页数:7
相关论文
共 39 条
  • [1] THREATS TO THE SCIENTIFIC INTEGRITY OF CLINICAL-TRIALS
    FOSTER, RS
    [J]. ARCHIVES OF SURGERY, 1994, 129 (06) : 571 - 573
  • [2] Implementing clinical trials on an international platform: Challenges and perspectives
    Minisman, Greg
    Bhanushali, Minal
    Conwit, Robin
    Wolfe, Gil I.
    Aban, Inmaculada
    Kaminski, Henry J.
    Cutter, Gary
    [J]. JOURNAL OF THE NEUROLOGICAL SCIENCES, 2012, 313 (1-2) : 1 - 6
  • [3] Ethical and scientific challenges of placebo control arms in clinical trials
    De Deyn P.P.
    [J]. International Journal of Pharmaceutical Medicine, 2000, 14 (3) : 149 - 157
  • [4] Implementing Liquid Biopsies in Clinical Trials State of Affairs, Opportunities, and Challenges
    Lustberg, Maryam B.
    Stover, Daniel G.
    Chalmers, Jeffrey J.
    [J]. CANCER JOURNAL, 2018, 24 (02): : 61 - 64
  • [5] Need for and Challenges Facing Functional Communication as Outcome Parameter in AD Clinical Trials
    Haberstroh, Julia
    Wollstadt, Patricia
    Knebel, Maren
    Oswald, Frank
    Schroeder, Johannes
    Pantel, Johannes
    [J]. ALZHEIMER DISEASE & ASSOCIATED DISORDERS, 2013, 27 (04): : 293 - 301
  • [6] Enhancing the Scientific Integrity and Safety of Clinical Trials Recommendations for Data Monitoring Committees
    Lewis, Roger J.
    Calis, Karim A.
    DeMets, David L.
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2016, 316 (22): : 2359 - 2360
  • [7] Research integrity in clinical trials: innocent errors and spin versus scientific misconduct
    Nunez-Nunez, Maria
    Andrews, Jeffrey C.
    Fawzy, Mohamed
    Bueno-Cavanillas, Aurora
    Khan, Khalid Saeed
    [J]. CURRENT OPINION IN OBSTETRICS & GYNECOLOGY, 2022, 34 (05) : 332 - 339
  • [8] The challenges and achievements involved in implementing Quality of Life research in cancer clinical trials
    Bottomley, A
    Vanvoorden, V
    Flechtner, H
    Therasse, P
    [J]. EUROPEAN JOURNAL OF CANCER, 2003, 39 (03) : 275 - 285
  • [9] Challenges of implementing ancillary studies within multi-site clinical trials
    Chay, T
    Goodman, P
    Hartline, JA
    [J]. CONTROLLED CLINICAL TRIALS, 2003, 24 : 182S - 183S
  • [10] Design challenges facing clinical trials of the effectiveness of new HIV-prevention technologies
    Grobler, Anneke C.
    Karim, Salim S. Abdool
    [J]. AIDS, 2012, 26 (05) : 529 - 532